Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00184652
First received: September 13, 2005
Last updated: November 18, 2013
Last verified: November 2013

September 13, 2005
November 18, 2013
April 2003
September 2005   (final data collection date for primary outcome measure)
Change in surrogate markers of nutrition [ Time Frame: After 6 months treatment ] [ Designated as safety issue: No ]
Change in surrogate markers of nutrition after 6 months treatment
Complete list of historical versions of study NCT00184652 on ClinicalTrials.gov Archive Site
  • Quality of Life [ Designated as safety issue: No ]
  • Other markers of nutrition [ Designated as safety issue: No ]
  • Quality of Life
  • other markers of nutrition
Not Provided
Not Provided
 
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Chronic Kidney Disease
  • End-Stage Renal Disease
Drug: somatropin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
September 2005
September 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ESRD patients

Exclusion Criteria:

  • Diabetes Mellitus
  • Severe and Malignant diseases
  • Patients in Intensive Care Units
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Denmark,   France,   Germany,   Hong Kong,   Israel,   Poland,   Singapore,   Sweden,   Switzerland,   United Kingdom
 
NCT00184652
NN1606-1442
No
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Anders Dejgaard, MD Novo Nordisk A/S
Novo Nordisk A/S
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP